New drug for skin cancer reported

Michelle Fernandez

This is AI generated summarization, which may have errors. For context, always refer to the full article.

Erivedge, a new drug that could fight two rare types of skin cancer, was approved by the US Food and Drug Administration after an expedited review. Produced by a US subsidiary of Swiss drug giant Roche, Erivedge or vismodegib has been found to help some patients with two kinds of basal cell carcinoma, the most common form of skin cancer in the world. Studies showed that the drug retarded the growth of new tumors but also produced side effects such as loss of taste, hair loss and muscle cramps. More study is needed to determine how long it may work to ward off cancer, when it should be optimally administered, and what populations it may best serve.

Read the full story on Rappler

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.

Summarize this article with AI

How does this make you feel?

Loading
Download the Rappler App!